Clinical Trial Update: Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating camrelizumab with SRT/WBRT and chemotherapy in brain metastases from driver gene-negative non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non-Small-Cell Lung Cancer | Phase 3 | Status: UNKNOWN